Abrezekimab Biosimilar - Research Grade

Human

IL13

>1mg/ml

Fab - G1 - kappa

CHO Cells

Lebrikizumab Biosimilar - Research Grade (ICH5058), Tralokinumab Biosimilar - Research Grade (ICH5059), Anrukinzumab Biosimilar - Research Grade (ICH5347), Cendakimab Biosimilar - Research Grade (ICH5432), Dectrekumab Biosimilar - Research Grade (ICH5470), Riltovetbart Biosimilar - Research Grade (ICH5822)

https://www.imgt.org/mAb-DB/

ICH3002

P35225

Blue ice

This product is a research-grade biosimilar of abrezekimab, supplied as an unconjugated, non-therapeutic analog of the originator molecule for research use only. Abrezekimab (also known as CDP7766 and UCB4144) is a humanized, high-affinity, neutralizing antibody fragment directed against human interleukin-13 (IL-13). Unlike a full-length IgG, it is provided in a Fab format (G1, kappa framework), reflecting the originator's design as an antibody fragment engineered for potent IL-13 neutralization. The Fab binds the region of IL-13 involved in receptor engagement and prevents the cytokine from associating with its receptor subunits, thereby blocking downstream IL-13 signaling. As a biosimilar research reagent, this material is intended for functional and in-vitro characterization work rather than clinical application. Ichor supplies it at research grade with low endotoxin, in bulk milligram-to-gram quantities, as an in-vivo-capable standard where an appropriate model exists. It serves as a defined, reproducible benchmark tool for investigators studying IL-13 biology, type 2 inflammation, and neutralizing-antibody mechanisms. Because the target is a human cytokine, the reagent is used primarily in binding, neutralization, and control applications. Interleukin-13 (IL-13; UniProt P35225) is a pleiotropic type 2 cytokine produced chiefly by activated Th2 cells, as well as by mast cells, basophils, and innate lymphoid cells. It is a central driver of allergic and type 2 inflammation and shares many biological activities with IL-4. IL-13 signals through a receptor complex involving IL-13Rα1 paired with IL-4Rα, activating STAT6-dependent transcription; it also binds the high-affinity decoy receptor IL-13Rα2. Functionally, IL-13 promotes B-cell proliferation and IgE class switching, mucus production and goblet-cell hyperplasia, smooth-muscle changes, fibrosis, and recruitment and activation of eosinophils, basophils, and mast cells. These effects make IL-13 a well-established therapeutic and research target in asthma, atopic dermatitis, and other allergic and fibrotic conditions. Neutralizing IL-13 prevents its engagement with the signaling receptor and blocks these downstream inflammatory responses.

Interleukin-13, NC30

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks